Why the study?
Does serum lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) predict recurrence and survival in patients undergoing curative surgical treatment for hepatocellular carcinoma?
Does serum lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) predict recurrence and survival in patients undergoing curative surgical treatment for hepatocellular carcinoma?
Postoperative AFP-L3 is a significant independent predictor of recurrence and survival in patients undergoing curative surgery for hepatocellular carcinoma.
May refine post-resection risk stratification in HCC; leaves open whether it should guide adjuvant decisions.
The clinical significance of serum lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3), which can distinguish between hepatocellular carcinoma and hepatitis by detecting a sugar chain micro heterogeneity, was evaluated for its possible ability to recognize previously undetectable residual tumors, and for increasing the accuracy of prognosis after surgical treatment for hepatocellular carcinoma. Serum lens culinaris agglutinin-reactive alpha-fetoprotein was measured pre- and post-operatively in 130 patients who underwent curative surgical treatment for hepatocellular carcinoma. The preoperative AFP-L3 positive rate was 35.4%. AFP-L3 remained positive postoperatively in 28 of the 46 preoperative AFP-L3 positive patients, and converted to positive in 4 of the 84 preoperative AFP-L3 negative patients. Regardless to preoperative AFP-L3, the postoperative AFP-L3 positive patients had a poorer recurrence-free rate (p<0.0001). The postoperative L3 positive patients had a high incidence of recurrence due to metastasis, but did not have recurrence due to multicentric origin. Multivariate analysis revealed that AFP-L3 (p<0.0001) was the most independently significant factor for predicting survival after surgery among several conventional prognostic factors. Thus, AFP-L3 is a valuable marker for evaluation of curability of surgical treatment and for improving the accuracy of prognosis.
No takes yet. Share an insight, caveat, or question.
Okuda et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: